Frequency of cognitive impairment in patients with parkinson\u27s disease by Teihmour, Mehmood et al.
eCommons@AKU
Department of Surgery Department of Surgery
May 2019
Frequency of cognitive impairment in patients with
parkinson's disease
Mehmood Teihmour
Mir Ali Asghar Ali
Maha Ali
Habiba D. Barry
Syed Zohaib Maroof Hussain
Aga Khan University
See next page for additional authors
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_surg
Recommended Citation
Teihmour, M., Asghar Ali, M., Ali, M., Barry, H. D., Maroof Hussain, S., Shahzad, H., Ramzan, A. (2019). Frequency of cognitive
impairment in patients with parkinson's disease. Cureus, 11(5), 1-8.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_surg/796
Authors
Mehmood Teihmour, Mir Ali Asghar Ali, Maha Ali, Habiba D. Barry, Syed Zohaib Maroof Hussain, Huma
Shahzad, and Amber Ramzan
This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_surg_surg/796
Received 05/12/2019 
Review began 05/14/2019 
Review ended 05/15/2019 
Published 05/23/2019
© Copyright 2019
Taimur et al. This is an open access
article distributed under the terms of
the Creative Commons Attribution
License CC-BY 3.0., which permits
unrestricted use, distribution, and
reproduction in any medium, provided
the original author and source are
credited.
Frequency of Cognitive Impairment in
Patients with Parkinson’s Disease
Muhammad Taimur  , Mir Ali Asghar Shah  , Maha Ali  , Habiba D. Barry  , Syed Zohaib
Maroof Hussain  , Huma Shahzad  , Amber Rizwan 
1. Internal Medicine, Dow University of Health Sciences, Karachi, PAK 2. Internal Medicine, Jinnah
Postgraduate Medical Center, Karachi, PAK 3. Surgery, Dow University of Health Sciences, Karachi, PAK
4. Miscellaneous, Dow University of Health Sciences, Karachi, PAK 5. Surgery, Aga Khan University
Hospital, Karachi, PAK 6. Family Medicine, Civil Hospital, Karachi, PAK
 Corresponding author: Amber Rizwan, amber_aljazeera109@hotmail.com 
Disclosures can be found in Additional Information at the end of the article
Abstract
Introduction
More than its motor symptoms, cognitive impairment is being increasingly identified as a cause
of worse functional outcome, morbidity and mortality, and caregiver dependence in
Parkinson’s disease (PD). The aim of this study was to identify the frequency of cognitive
decline and evaluate the factors associated with it.
Methods
In this cross-sectional study, 124 PD patients fulfilling the United Kingdom Parkinson’s Disease
Society Brain Bank Clinical Diagnostic Criteria were included. Motor and non-motor symptoms
were recorded. Disease duration, age at the time of onset, and severity of disease on Hoehn and
Yahr Scale (HY scale) were recorded. Data was entered and analyzed using SPSSs v. 22.0.
Results
The ratio of men to women was 7.2:1. The mean age of the participants was 64 ± 10 years
(range: 38-82 years). Rigidity (n = 121; 97.5%), bradykinesia (n = 119; 95.9%), and tremor (n =
11; 90.3%) were the three most common symptoms. Cognitive impairment was present in 45
(36.3%) patients. Cognitive decline was more frequent in patients of age less than 50 years at
the time of disease onset (p < 0.00001) and in those with disease duration more than 10 years
(p = 0.00001). Patients with longer disease duration had more severe disease (stage III or above
on HY scale; p = 0.008).
Conclusion
Motor symptoms such as rigidity, bradykinesia, and tremor remain the most frequent clinical
presentation among Pakistani Parkinson’s patients. One-third of these patients have cognitive
dysfunction. Early age at the time of disease onset and longer duration of disease were
associated with cognitive impairment.
Categories: Family/General Practice, Internal Medicine, Neurology
Keywords: parkinson disease, cognitive impairment, non-motor symptoms, cognitive deficits, pakistan
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Classically, Parkinson’s disease (PD) is a clinical triad of bradykinesia (slowness of
movements), rigidity (stiffness), and localized tremor present even at rest. Other than these
cardinal signs, the clinical presentation of PD is heterogeneous. It includes a varied spectrum of
motor and non-motor signs and symptoms. PD is a complex, progressive, neurodegenerative
disease with an individualized presentation in all patients [1].
PD is the second leading cause of age-related neurodegeneration. Globally, it is estimated that
10 million people are living with PD. The incidence increases with advancing age. Around
41/100,000 people in their fourth decade of life are living with PD; however, by age 80 years, the
incidence increases to 1900/100,000 people. Four percent of Parkinson’s population is
diagnosed at age less than 50 years [2].
Neurodegeneration in PD is characterized by pathogenetic fibrilization of α-synuclein protein
and Lewy body formation in the substantia nigra, limbic system, and the neocortex.
Neurodegenerative changes affect dopaminergic neurons in the substantia nigra, locus
coeruleus - main noradrenergic site, raphe nuclei - where serotoninergic neurons are located,
and nucleus basalis of Meynert, a part of the cholinergic complex in the basal forebrain. Hence,
there is disruption in the natural equilibrium among the dopamine, noradrenaline, serotonin,
and acetylcholine systems [3-4]. This underlying neuropathology is also supported by the
emergence of cognitive deficit in patients with PD. Most of the cognitive and also motor
functions are related to projections from the frontal lobes. Hence, it was suggested that
cognitive deficit in PD is related to disruptions in the prefrontal cortex-basal ganglia-
thalamocortical circuit [4].
Cognitive deficit presents as impairment in executive functions including, but not limited to,
problems with planning, working memory, and visuospatial attention. Later, it may progress
into clinically significant dementia. The onset of even mild cognitive impairment has been
established as a predictor of deteriorating functional outcome [3]. With the incidence of
dementia, the risk of mortality in PD patients increases by almost two folds [5-6].
Randomized control trials have shown promising outcomes with intensive cognitive training in
enhancing cognitive function in patients with PD [7]. However, the key to addressing the
cognitive decline in these patients is early recognition. The aim of this study is to evaluate the
spectrum of clinical features in patients with PD, identify the frequency of cognitive decline,
and evaluate the factors associated with cognitive decline in these patients.
Materials And Methods
In this cross-sectional study, conducted for one year (January to December 2018) in the
outpatient neurology clinic of a tertiary care hospital in Karachi, all patients with diagnosed PD
were invited to participate. This study was approved by the intuitional ethical committee and
informed consent was taken from the patient.
All of these patients were already registered in the Parkinson database of the department and
allotted a registration number. This registration number was recorded to not duplicate a patient
once enrolled in this study. The diagnosis of PD was made in accordance with the United
Kingdom Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria [8]. Patients with
incomplete clinical data, language barrier to communication, patients who did not agree to
participate, or patients who are unable to communicate even with the help of family member or
a doctor were excluded. Newly diagnosed cases (≤6 months to diagnosis) were also excluded. All
included patients had two features of PD, the presence of two of the three cardinal clinical
features: tremor, rigidity, and bradykinesia and response to levodopa.
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All patients were routinely examined by a qualified neurologist as a part of their follow-up
visits. The clinical findings updated by the neurologist in the patient files were accessed.
Patient gender, current age, age at the time of diagnosis, duration of diagnosis, and all clinical
symptoms were recorded. The severity of PD was evaluated on the Hoehn and Yahr Scale (HY
scale) that records the severity of motor symptoms from Stage I to IV [9]. Data was processed
and analyzed through SPSS for windows version 22.0 (NY, USA). Duration of diagnosis and age
were recorded as continuous variables and then categorized for analysis. Mean and standard
deviation (SD) was calculated for continuous variables. Frequencies and percentages were
calculated for categorical variables including gender, clinical symptoms, and severity of
disease. The correlation was calculated for the presence of cognitive decline with age at the
time of diagnosis and the duration of diagnosis. Duration of diagnosis was also correlated with
the severity of PD on HY scale. Chi-square was applied. P-value ≤0.05 was taken as significant.
Results
A total of 124 patients of PD were included in this study. There were 109 (87.9%) men and 15
(12.1%) women. The ratio of men to women was 7.2:1. The mean age of the participants was
63.57 ± 10.41 years (range: 38-82 years). Men were slightly older than women (65.35 ± 8.01
years vs. 62.18 ± 5.38 years). There were 55 (44.3%) participants who were younger than 50
years at the time of onset of their disease and 69 (55.6%) participants were older than 50 years
of age at that time. The mean duration of disease was 10.47 ± 3.58 years. There were 57 (45.9%)
participants with the duration of disease less than 10 years and 67 (54.1%) participants with
more than 10 years of living with the disease.
Rigidity (97.5%), bradykinesia (95.9%), and tremor (90.3%) were the three most common
symptoms present in the patients. Other signs such as hypomania (85.4%), primitive reflexes
(78.2%), monotonous speech (69.3%), problems with walking (68.5%), and fine motor
movement (62.9%) were also very common. Cognitive impairment was present in 45 (36.3%)
patients (Table 1).
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Hypomimia (Masked facies) 106 (85.4%)
Primitive reflexes 97 (78.2%)
Monotonous speech 86 (69.3%)
Difficulty walking 85 (68.5%)
Difficulty in fine work 78 (62.9%)
Constipation 72 (58.0%)
Bladder symptoms 67 (64.1%)
Stiffness 54 (54.0%)
Cognitive impairment/decline 45 (36.3%)
Falls 39 (31.5%)
Dysphagia 32 (25.8%)
Stooped posture 29 (23.3%)
Shuffling gait 21 (16.9%)
Micrographia 13 (10.4%)
TABLE 1: Clinical characteristics of patients with Parkinson’s disease (N = 124)
* Patients may have more than one clinical feature
Cognitive decline was correlated with the duration of disease and the patient’s age at the time
of onset of disease. Among patients with cognitive decline, 32 (71.1%) were younger than 50
years at the time of onset of their disease and 13 (28.9%) were older than 50 years. In patients
with no cognitive impairment, 23 (29.1%) were younger than 50 years at the time of onset of
their disease and 56 (70.9%) were older than 50 years (p < 0.00001). When cognitive decline was
correlated with duration of disease, it was seen that among patients with cognitive decline, 9
(20%) were diagnosed within 10 years and 36 (80%) have had this disease for more than 10
years. In patients with no cognitive impairment, 48 (60.7%) were diagnosed within 10 years and
31 (39.2%) have had this disease for more than 10 years (p = 0.00001; Table 2).
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Variables
PD patients with cognitive decline (n =
45)
PD patients with no cognitive decline (n =
79)
P value
Age of onset of disease
Less than 50
years












36 (80%) 31 (39.2%)
TABLE 2: Relationship of cognitive decline in Parkinson’s patients with age at onset
of disease and duration of disease (N = 124)
PD, Parkinson's disease
There were 51 (41.1%) patients at stage I and II and 73 (58.8%) patients at stage III and above
on HY scale. Duration of disease was then correlated with the severity of PD. There were 23
(18.5%) patients with duration of disease ≤5 years; 16 (69.5%) were at Stage I and II and seven
(30.5%) were at Stage III and above of PD. There were 34 (27.4%) patients with duration of
disease 6-9 years; of these, 11 (32.3%) were at Stage I and II and 23 (67.6%) were at Stage III and
above of PD. There were 67 (54.0%) patients with duration of disease ≥10 years; of these,
24 (35.8%) were at Stage I and II and 43 (64.2%) were at Stage III and above of PD (p = 0.008;
Table 3).
Duration of disease Stage I and II (n = 51) Stage III and above (n = 73) P value
≤5 years (n = 23) 16 (69.5%) 7 (30.5%)
0.0086-9 years (n = 34) 11 (32.3%) 23 (67.6%)
≥10 years (n = 67) 24 (35.8%) 43 (64.2%)
TABLE 3: Relationship of duration of disease with the severity of Parkinson’s disease
on Hoehn and Yahr Scale (N = 124)
Discussion
The clinical spectrum of PD varies from patient to patient; however, the cardinal clinical
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features such as rigidity, tremor, and bradykinesia remain the most commonly encountered
ones. Cognitive impairment was seen in more than one-third of the patients. Cognitive decline
was associated with early age of onset of the disease and longer disease duration. Longer
disease duration was also associated with higher severity of the disease on the HY scale.
As with other literature, there were more men with PD in this study too [10-11]. In a Japanese
study, female gender was more commonly associated with PD [12]. The mean age of
participants in this study was 63.57 ± 10.41 years. Comparable mean ages have been reported in
local (57-64.5 years) as well as international (71; range: 67-75 years) studies [11,13-14].
Among the common clinical signs of PD in this study, rigidity, bradykinesia, and tremor were
the most frequent. Similar results have been seen in other studies too. In some studies, non-
motor symptoms have been more commonly reported [10,15]. In this study, 63% patients with
PD showed signs of cognitive impairment. In a Nigerian study, 21% of PD patients have been
reported to have cognitive deficits as compared to only 4% of control population (p = 0.008).
However, they reported older age of onset as the independent predictor of cognitive
impairment, which is contradictory to this study where lower age at the time of onset was
associated with cognitive impairment [16]. In another recent study with 100 PD patients,
advancing age and tremor as the dominant symptom at the onset of disease were independently
correlated with poor cognitive function [17]. Among Pakistani patients of PD, cognitive deficit
has been previously reported to be in 19% patients which is almost half of those as reported in
this study [18-19]. In another recent Indian study, PD patients with disease duration > 10 years
scored lowest on Scales for Outcomes in PD Cognition (SCOPA-COG) as compared to those with
one to five and six to nine years of disease [20]. Their results of advancing cognitive
impairment with increasing duration were not statistically significant, however, ours were.
The major limitation of this study was the lack of any clinical or neurological follow-up. There
was no neuropsychological testing done via validated instruments. Diagnosis of cognitive
impairment was made by consultant neurologists and can be subjected to human error study
did not identify is study has its shortcomings too. Although, this center is the largest
neurological care center in the province and deals with huge chunks of patients; it is still a
single-center study. It also did not evaluate the subtype of cognitive deficit and whether or not
dementia had ensued. Further cohort studies with a population-based sample must be initiated
to evaluate cognitive function status in patients with PD and form the basis to new therapeutic
options for delaying dementia in these patients.
Conclusions
The present study revealed that motor symptoms such as rigidity, bradykinesia, and tremor
remain the most frequent clinical presentation among Pakistani Parkinson’s patients. One-
third of these patients have cognitive dysfunction. Early age at the time of disease onset and
longer duration of disease were associated with cognitive impairment. However, a population-
based cohort with longer follow-up will provide a more accurate picture of the factors
predicting cognitive impairment in patients with Parkinson’s.
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